MedPath

Is More Than One Dose of Misoprostol Needed to Expedite Vaginal Delivery in a Patient With an Unripe Cervix?

Phase 2
Completed
Conditions
Labor; Forced or Induced, Affecting Fetus or Newborn
Interventions
Registration Number
NCT02680314
Lead Sponsor
Montefiore Medical Center
Brief Summary

The goal of this study is to determine whether inducing labor with just one dose of misoprostol, followed by treatment with oxytocin, will still be effective enough to increase the chances of having a successful vaginal delivery as compared to using more than one dose of misoprostol, followed by treatment with oxytocin.

Detailed Description

This study involves a comparison of two different regimens of prostaglandin use for "cervical ripening" prior to induction of labor. Women admitted to the hospital for induction of labor who are found to have "unripe" cervixes at the time of admission, and who agree to participate in the study will be randomly assigned to one of two treatment groups. In one group, a single dose of 25 µcg of misoprostol will be administered vaginally and four hours later oxytocin induction will be started if clinically indicated. In the second group of women, repeat doses of misoprostol will be given every four hours up to six doses unless labor or cervical ripening occurs sooner. At this point, oxytocin will be started as needed. Success of vaginal delivery by 24 hours, time from initiation of protocol to delivery and cesarean section rates will be compared. Complications such as postpartum hemorrhage, episodes of tachysystole with fetal compromise and chorioamnionitis and endometritis will be monitored.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
243
Inclusion Criteria
  • Any pregnant woman undergoing induction of labor
  • Live singleton pregnancy ≥ 37 week gestation
  • Bishop score < 6
  • Category I fetal heart rate
Exclusion Criteria
  • Contraindications to vaginal delivery (e.g. vasa previa, placenta prevue,non-vertex presentation, umbilical cord prolapse, and active genital herpes infection.)
  • Pregnancies complicated by major fetal anomalies
  • Any contraindication to the use of misoprostol, including
  • History of previous c-section or major uterine surgery
  • Prior allergic reaction
  • Category II or III fetal heart rate
  • Regular uterine contractions ≥ 3 in a 10-minute period persistent for at least 30 minutes
  • Estimated fetal weight < 10 percentile
  • Premature rupture of membranes
  • Age < 18 years old
  • Women who do not have the capacity to consent

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Multiple DoseMisoprostolmultiple doses of misoprostol
Single DoseMisoprostolsingle dose of misoprostol
Primary Outcome Measures
NameTimeMethod
Number of Participants With Vaginal Delivery Within 24 Hourswithin 24 hours

To compare the rate of vaginal delivery within 24 hours in patients who receive a single dose of misoprostol versus those receiving multiple doses of this medication.

Secondary Outcome Measures
NameTimeMethod
To Determine the Interval From Initiation of Misoprostol to Delivery in Each Groupwithin 24 hours from the initial intervention

To determine the interval from initiation of misoprostol to delivery in each group

© Copyright 2025. All Rights Reserved by MedPath